Encompass Health Co. (NYSE:EHC - Get Free Report) has been given an average rating of "Buy" by the eleven analysts that are presently covering the stock, Marketbeat reports. Nine equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $107.67.
EHC has been the topic of several analyst reports. Barclays lifted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. William Blair reiterated an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. StockNews.com lowered shares of Encompass Health from a "buy" rating to a "hold" rating in a research report on Thursday, April 3rd. KeyCorp lifted their price target on shares of Encompass Health from $117.00 to $120.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $110.00 price objective on shares of Encompass Health in a research report on Tuesday, February 11th.
Read Our Latest Analysis on EHC
Insider Buying and Selling
In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares of the company's stock, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Encompass Health
A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Encompass Health by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock worth $960,817,000 after purchasing an additional 138,196 shares during the last quarter. Invesco Ltd. lifted its holdings in Encompass Health by 3.3% during the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock valued at $511,273,000 after buying an additional 176,135 shares in the last quarter. State Street Corp raised its stake in shares of Encompass Health by 0.7% during the third quarter. State Street Corp now owns 3,025,769 shares of the company's stock valued at $292,410,000 after acquiring an additional 21,329 shares in the last quarter. Alliancebernstein L.P. grew its stake in Encompass Health by 6.0% in the fourth quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company's stock worth $191,799,000 after purchasing an additional 117,617 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Encompass Health by 0.8% in the 4th quarter. FMR LLC now owns 1,973,846 shares of the company's stock worth $182,285,000 after buying an additional 15,831 shares during the period. 97.25% of the stock is owned by institutional investors.
Encompass Health Stock Performance
Shares of EHC traded down $0.96 during trading hours on Thursday, hitting $102.30. The stock had a trading volume of 775,382 shares, compared to its average volume of 662,645. Encompass Health has a 12 month low of $78.53 and a 12 month high of $104.55. The stock has a fifty day moving average price of $99.66 and a 200 day moving average price of $98.11. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The firm has a market capitalization of $10.30 billion, a PE ratio of 22.94, a PEG ratio of 2.31 and a beta of 0.87.
Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Analysts anticipate that Encompass Health will post 4.8 EPS for the current year.
Encompass Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 annualized dividend and a yield of 0.66%. Encompass Health's payout ratio is currently 15.25%.
Encompass Health Company Profile
(
Get Free ReportEncompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
See Also
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
